Technology | Artificial Intelligence | July 18, 2019

Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s QuantX software is used to assist radiologists in assessment and characterization of breast lesions

Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

July 18, 2019 — Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded to harness the value of artificial intelligence (AI) to improve medical outcomes. Qlarity Imaging will further develop QuantX, the U.S. Food and Drug Administration (FDA)-cleared computer-aided breast cancer diagnosis system. 

Qlarity plans to expand the diagnostic applications of its AI technology to additional imaging modalities and medical conditions, with the goal of improving patient care while lowering costs for hospitals and payers. 

Qlarity Imaging acquired QuantX, the medical imaging AI system with intuitive displays, advanced analytics and machine learning, initially developed at the University of Chicago based on research led by Maryellen L. Giger, Ph.D., and incubated at Quantitative Insights, a startup that had been launched with the support of the University of Chicago’s Polsky Center for Entrepreneurship and Innovation. A clinical study demonstrated the effectiveness of QuantX at helping radiologists interpret cancerous and non-cancerous breast lesions — the results showed a 39 percent reduction in missed breast cancers without a reduction in specificity, as well as a 20 percent overall diagnostic improvement. The study led to the FDA clearance of the AI technology for breast cancer.

Paragon’s capabilities and investment in Qlarity Imaging provide Qlarity with the working capital needed to further develop and implement its computer-aided diagnosis system and explore expanded uses of AI-enabled diagnostic tools. Paragon Biosciences advises its portfolio companies on how to leverage AI technology to enhance the diagnostic insight of medical devices, accelerate the pace of drug development, and increase the efficacy of novel therapies.

Qlarity’s AI-enabled image processing and diagnostic algorithms are based on decades of research by Giger, a pioneer in the field of computer-aided diagnosis. Now an advisor to Qlarity Imaging, Giger has conducted more than 30 years of research in computer-aided diagnosis, including computer vision and machine learning for breast cancer, lung cancer, prostate cancer, lupus and bone diseases.

“When we looked at how to best commercialize and scale QuantX, the computer-aided diagnostic system originally developed at the University of Chicago, Paragon Biosciences was the perfect partner,” Giger said. “Paragon is already delivering on its promise, helping Qlarity Imaging to expand its management team, pursue new product opportunities, extend its customer base and seek additional venture financing.”

For more information: www.qlarityimaging.com

Related Content

Major Radiology Organizations Publish Ethics of AI in Radiology Statement
News | Artificial Intelligence | October 22, 2019
Experts in the use of artificial intelligence (AI) in radiology, from many of the world’s leading radiology, medical...
GE Healthcare and Premier Inc. Developing One-stop Breast Clinic Model for U.S.
News | Mammography | October 21, 2019
GE Healthcare and Premier Inc. have announced a collaboration to develop a model to bring a same-day breast cancer...
Densitas Breast Density Assessment Software Joins Nuance AI Marketplace
News | Breast Density | October 21, 2019
Densitas Inc. announced that its U.S. Food and Drug Administration (FDA)-cleared densitas densityai breast density...
FDA Clears AiCE Image Reconstruction on Canon's Aquilion Precision CT

Image courtesy of Canon Medical Systems

Technology | Computed Tomography (CT) | October 21, 2019
Canon Medical Systems USA Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance on its Advanced...
The Revolution Apex intelligent computed tomography (CT) scanner

The Revolution Apex intelligent computed tomography (CT) scanner. Image courtesy of GE Healthcare.

News | RSNA | October 18, 2019
At the 2019 annual meeting of the Radiological Society of North America (RSNA 2019), Dec. 1-6 in Chicago, GE Healthcare...
Selecting an AI Marketplace for Radiology: Key Considerations for Healthcare Providers
Feature | Artificial Intelligence | October 18, 2019 | Sanjay Parekh, Ph.D.
October 18, 2019 — As the nascent market for...
MaxQ AI's Intracranial Hemorrhage Software to be Integrated on Philips CT Systems
News | Artificial Intelligence | October 18, 2019
Medical diagnostic artificial intelligence (AI) company MaxQ AI announced that its Accipio intracranial hemorrhage (ICH...
While electronic medical record systems have helped consolidate most patient data into one location, medical imaging IT systems has proved to be more difficult to replicate by large EMR vendors. This has made room in the market for third-party radiology IT vendors that allow easy integration with the larger EMRs like Epic and Cerner. This image shows Agfa's enterprise imaging system, leveraging its ability to be accessed anywhere with internet connection and pull images from radiology and surgery.

While electronic medical record systems have helped consolidate most patient data into one location, medical imaging IT systems has proved to be more difficult to replicate by large EMR vendors. This has made room in the market for third-party radiology information system vendors that allow easy integration with the larger EMRs like Epic and Cerner. This image shows Agfa's enterprise imaging system, leveraging its ability to be accessed anywhere with an internet connection and able to pull in images from both radiology and surgery. 

Feature | Enterprise Imaging | October 17, 2019 | Steve Holloway
October 17, 2019 — The growing influence and uptake of electronic medical records (EMRs) in healthcare has driven deb
A patient prepares to have a tomosynthesis-guided prone breast biopsy using the Hologic Affirm prone biopsy system.

A patient prepares to have a tomosynthesis-guided prone breast biopsy using the Hologic Affirm prone biopsy system.

Feature | Breast Biopsy Systems | October 17, 2019 | By Harriet Borofsky, M.D.
The current body of research supporting...